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ORIGINAL ARTICLE
Abnormal error processing in depressive states: a translational
examination in humans and rats
C Beard1, RJ Donahue1, DG Dillon1, A Van’t Veer1, C Webber1, J Lee1, E Barrick1, KJ Hsu1, D Foti1, FI Carroll2, WA Carlezon Jr1,
T Björgvinsson1 and DA Pizzagalli1
Depression has been associated with poor performance following errors, but the clinical implications, response to treatment and
neurobiological mechanisms of this post-error behavioral adjustment abnormality remain unclear. To ﬁll this gap in knowledge, we
tested depressed patients in a partial hospital setting before and after treatment (cognitive behavior therapy combined with
medication) using a ﬂanker task. To evaluate the translational relevance of this metric in rodents, we performed a secondary
analysis on existing data from rats tested in the 5-choice serial reaction time task after treatment with corticotropin-releasing factor
(CRF), a stress peptide that produces depressive-like signs in rodent models relevant to depression. In addition, to examine the
effect of treatment on post-error behavior in rodents, we examined a second cohort of rodents treated with JDTic, a kappa-opioid
receptor antagonist that produces antidepressant-like effects in laboratory animals. In depressed patients, baseline post-error
accuracy was lower than post-correct accuracy, and, as expected, post-error accuracy improved with treatment. Moreover, baseline
post-error accuracy predicted attentional control and rumination (but not depressive symptoms) after treatment. In rats, CRF
signiﬁcantly degraded post-error accuracy, but not post-correct accuracy, and this effect was attenuated by JDTic. Our ﬁndings
demonstrate deﬁcits in post-error accuracy in depressed patients, as well as a rodent model relevant to depression. These deﬁcits
respond to intervention in both species. Although post-error behavior predicted treatment-related changes in attentional control
and rumination, a relationship to depressive symptoms remains to be demonstrated.
Translational Psychiatry (2015) 5, e564; doi:10.1038/tp.2015.54; published online 12 May 2015
INTRODUCTION
Cognitive impairment is a debilitating component of
depression.1,2 Deﬁcits in cognitive control—the ability to mod-
ulate behavior in order to meet ﬂuctuating environmental
demands or internal goals—precede the onset of depressive
symptoms,3 persist following symptom remission4,5 and predict
poor response to treatment.6 Cognitive control impairments may
be particularly salient in the context of perceived failure.7–11
Indeed, several prior studies found that following an incorrect
response—but not a correct response—performance (for exam-
ple, accuracy) deteriorates in clinical and subclinical-depressed
samples, a phenomenon described as ‘catastrophic response to
perceived failure’.8 Despite these intriguing ﬁndings, compared
with other cognitive control impairments, we know little about the
clinical correlates and neurobiological substrates of abnormal
post-error behavioral adjustments. To date, no studies have
examined whether they can be ameliorated by treatment or
whether they predict treatment response. Moreover, no studies
have determined whether an analogous phenomenon exists in
rodents, in part, because of difﬁculties in modeling depression in
this species. The existence of these signs in rats in response to
manipulations that produce depressive-like behaviors might
facilitate translational studies and thus provide insight on
mechanisms and sensitivity to existing or novel interventions.
The current study examined post-error behavioral adjustment in
depression by integrating behavioral data from depressed
patients undergoing treatment and from rodents (rats) given a
manipulation known to produce hallmark signs of depression.
First, in the human study, we examined the effect of treatment on
post-error behavior elicited during an arrow ﬂanker task. Treat-
ment consisted of intensive cognitive-behavioral therapy (CBT)
and pharmacological medication in a partial hospital setting.
Although the evidence for a positive effect of depression
treatment on cognitive impairments is mixed,12–14 we expected
that patients would show improved post-error behavioral adjust-
ments following treatment because CBT speciﬁcally targets
negative cognitive schemas related to failure, and thus should
decrease the impact of perceived failure on performance. Given
that other types of cognitive impairment predict poor response to
treatment, we also expected to ﬁnd a positive relationship
between pretreatment post-error behavioral adjustment and
treatment outcomes. This was based on a two-part hypothesis:
(1) post-error behavioral adjustments depend on the deployment
of cognitive control and (2) participants who could capably exert
cognitive control at baseline would be most likely to beneﬁt
from CBT.
We adopted a translational approach to investigate neurobio-
logical mechanisms associated with abnormal post-error behav-
ioral adjustments. To this end, we performed proof-of-concept
secondary analyses of data from a rodent study15 to (1) examine
whether post-error accuracy is impaired when rats are given a
manipulation known to produce depressive-like behaviors, and (2)
determine whether such effects could be mitigated by an
intervention that produces antidepressant-like effects. Speciﬁcally,
we examined the effects of corticotropin-releasing factor (CRF) on
performance in the 5-choice serial reaction time task (5CSRTT)—a
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behavioral procedure widely used to quantify attention in rats.16,17
CRF has a critical role in the physiological response to stress and
has been implicated in the pathophysiology of anxiety and
depression.18,19 Indeed, individuals with mood disorders exhibit
higher levels of CRF in cerebrospinal ﬂuid.20,21 CRF administration
is known to induce depression- and anxiety-like phenotypes in
rodents,22,23 and we have previously found that CRF infusion
degrades 5CSRTT performance, yielding decreases in correct
responding, increased omission errors, increased latencies to
respond correctly and increased time needed to complete the test
session.15 Here, we present a novel analysis of CRF effects on post-
error adjustments. We also examined the effect of a pharmaco-
logical intervention in the rats: speciﬁcally, we tested whether
administration of JDTic—a kappa-opioid receptor (KOR) antago-
nist with antidepressant- and anxiolytic-like effects that can
attenuate CRF-induced attention deﬁcits15,24—would likewise
ameliorate post-error performance impairments.
STUDY 1: PATIENTS
Patients and treatment
Data were collected from patients receiving treatment for a mood
disorder at the Behavioral Health Partial Hospital Program at
McLean Hospital, Belmont, MA, USA. The partial hospital delivers
brief, intensive group, and individual CBT and pharmacological
treatment to individuals with a range of psychiatric disorders
(principally mood, anxiety, personality and psychotic disorders;
see Beard and Björgvinsson25 for details). Individual treatment
plans are constructed for each patient by clinical team managers
who conduct initial intake assessments, develop an initial
conceptualization, identify a problem list for patients and oversee
all aspects of treatment in conjunction with a program
psychiatrist. Treatment consists primarily of group CBT provided
by psychologists, social workers, occupational therapists, nurses,
postdoctoral and graduate level psychology trainees and mental
health counselors. Patients attend up to ﬁve 50-min groups each
day, 5 days per week (Monday–Friday), and 2–3 weekly individual
CBT sessions. Finally, patients also meet with a program
psychiatrist for medication management. The average duration
of treatment is ~ 8 days. All patients received a similar type,
intensity and duration of CBT (that is, primarily group format, daily
and brief—o2 weeks) targeting depression.
Eligibility criteria included a current mood disorder and being
stable enough to complete a research protocol (that is, not
actively psychotic). Of 88 eligible participants, 63 had complete
data, and the remaining 25 did not complete either the Time 1 or
Time 2 ﬂanker task for a variety of reasons (for example,
scheduling conﬂicts). Of the participants with complete data, 31
did not meet quality control cutoffs for examination of post-error
behavioral adjustments (see below and Supplementary Material),
resulting in 32 ﬁnal participants. Excluded participants did not
differ from those in the ﬁnal sample on baseline demographic or
clinical variables, with the exception of lower scores on the
BASIS-24 (Behavior and Symptom Identiﬁcation Scale) relationship
subscale, t(88) = 2.31, P= 0.023.
Participants were primarily single (n= 23), female (n= 22),
middle-aged (M= 29.97 years old, s.d. = 12.00) and reported the
following ethnoracial backgrounds: non-Latino white (n= 25),
multiracial (n= 3), Latino (n= 2) and no answer (n= 2). Psychiatrists
assigned diagnoses for all patients based on chart history and
clinical interview. Mood disorders included major depressive
disorder (n= 21), bipolar I disorder (n= 5), bipolar II disorder (n= 2)
and mood disorder not otherwise speciﬁed (n= 4). All patients
were depressed upon admission to the partial hospital. Of those
participants with information on comorbid disorders from a
structured interview (n= 21), the most common current comorbid
Diagnostic and Statistical Manual-IV Axis I diagnoses were
generalized anxiety disorder (n= 9), post-traumatic stress disorder
(n= 4), social anxiety disorder (n= 4), panic disorder (n= 4) and
alcohol dependence (n= 3). The average number of comorbid Axis
I disorders was 1.75 (s.d. = 1.77). Medication data were available
from medical charts for 27 participants, and most of these
individuals (n= 23) were receiving pharmacological treatment
upon admission to the partial hospital (antidepressant: n= 19,
antianxiety: n= 11, mood stabilizer: n= 9, antipsychotic: n= 8,
range= 0–7 medications; M= 2.44 and s.d. = 1.63).
Procedures
The local institutional review board approved all procedures, and
patients provided informed written consent. Patients completed
the ﬂanker task on the following two occasions: on their ﬁrst full
day of treatment (that is, second day in the program; Time 1) and
discharge day (Time 2). On average, these sessions were separated
by 11.22 days (s.d. = 2.92). Admission and discharge assessments
included self-report measures collected and managed using
REDCap electronic data capture tools hosted at McLean
Hospital.26 Participants completed a structured diagnostic inter-
view at Time 1. To improve the retention rate for the second
experimental session, we began compensating participants near
the end of data collection. Fourteen participants (seven with
complete data and ﬂanker data meeting quality control cutoffs)
received $25 for completing the discharge ﬂanker task (their
ﬁndings did not differ from participants without compensation;
ﬁndings available upon request).
Instruments
Depressive symptoms were assessed with the Center for
Epidemiologic Studies Depression Scale-10 (CESD-10).27 The
revised BASIS-24 was used to assess depression, difﬁculty with
relationships, self-harm, emotional lability, psychotic symptoms
and substance abuse.28 Use of cognitive-behavioral skills was
measured with the Cognitive Behavior Therapy Skills Question-
naire (CBTSQ-16).29 We assessed rumination with the Ruminative
Responses Scale (RRS),30 which measures two types of rumination:
brooding, which entails passively dwelling on the causes and
consequences of low mood, and is considered a maladaptive form
of rumination, and reﬂection, which is characterized by a more
distanced, problem-solving stance directed at the same issues and
is considered more adaptive. We also administered the Attentional
Control Scale (ACS),31 a 20-item measure that probes the capacity
to concentrate despite distracters or distress. Low ACS scores have
been previously associated with increased depressive and anxiety
symptoms, worry and difﬁculties redirecting attention away from
anxious and ruminative thoughts.31–35 The RRS and ACS were
administered immediately following the ﬂanker task, and were
added to the assessment battery shortly after initial data
collection; thus, 23 out of 32 participants completed these
measures. Finally, the Mini International Neuropsychiatric Inter-
view (MINI)36 was used to assess comorbid diagnoses (see Beard
and Björgvinsson37 for details on training and reliability).
Flanker task
Participants completed an arrow ﬂanker task.38,39 On each trial,
ﬂanking arrows appeared ﬁrst (duration: 100ms) and were then
joined by a center arrow (50ms) for a total stimulus duration of
150ms. On congruent trials, the center and ﬂanking arrows
pointed in the same direction (ooooo or 44444),
whereas on incongruent trials they pointed in opposite directions
(oo4oo or 44o44). The task was to indicate whether
the central arrow pointed left or right by pressing one of two
buttons on a keyboard as quickly as possible. Stimulus presenta-
tion was followed by a ﬁxation cross (1400ms). Each participant
completed 30 practice trials (15 congruent and 15 incongruent)
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followed by ﬁve blocks of 70 trials (46 congruent and 24
incongruent). To ensure that enough errors were committed to
allow analyses of post-error behavioral adjustments, block-by-
block feedback was added after data collection had started (see
Supplementary Material for details).
The main variables of interest were post-error accuracy ( =%
correct/total trials following an incorrect response) and reaction
time (RT), as well as post-correct accuracy ( =% correct/total trials
following a correct response) and RT. Moreover, post-error
adjustments were captured by computing the Laming effect
(AccuracyAfter Incorrect Trials−AccuracyAfter Correct Trials) and the
Rabbitt effect (RTAfter Incorrect Trials− RTAfter Correct Trials).
40,41 Positive
Laming and Rabbitt effects index more adaptive post-error
behavioral adjustments. As in prior studies, the post-error analyses
were limited to trials that followed incongruent errors in order to
disentangle post-error adjustments from congruency sequence
effects.10,42
Data analysis
To evaluate whether treatment reduced symptoms, paired t-tests
were performed on CESD-10 and ACS total scores. For the
BASIS-24, a multivariate analysis of variance (ANOVA) was
performed with Time (Time 1 and Time 2) and BASIS Subscore
(depression functioning, relationships, self-harm, emotional labi-
lity, psychosis and substance abuse) as factors. Similar Time× CBT
Subscore (behavioral activation and cognitive restructuring) and
Time× RRS Subscore (brooding and reﬂective) multivariate ANOVA
examined effects of treatment on CBT skill use and rumination. To
determine whether treatment affected post-error behavioral
adjustments, separate Time (Time 1 and Time 2) × Condition
(post-error and post-correct) ANOVAs were run for accuracy and
RT. Throughout the analyses, signiﬁcant effects were followed up
with paired t-tests.
Hierarchical regressions were run to test the hypothesis that
baseline post-error adjustments (Laming or Rabbitt effect) would
predict treatment outcome, as measured by the CESD-10, ACS and
RRS. In the ﬁrst set of regressions, Time 2 CESD-10 score was the
criterion variable, and Time 1 CESD-10 score and T1 post-error
effects were entered as predictors in the ﬁrst and second steps,
respectively. In the second set of regressions, Time 2 RRS subscore
(brooding or reﬂection) served as the criterion variable. Time 1 RRS
subscore, Time 1 CESD-10 score and Time 2 CESD-10 score were
entered as predictors in the ﬁrst, second and third steps,
respectively, and the Time 1 post-error effects were entered in
the fourth step. This approach investigates the relationship
between the post-error effect (at Time 1) and rumination (at Time
2) while controlling for rumination at Time 1 and depressive
symptoms at both times. The third set of regressions was identical,
except that ACS scores were used in place of RRS scores.
Signiﬁcant effects were followed up with separate regressions
for post-correct and post-error responses. In light of prior ﬁndings
highlighting differences between depressed and control sample in
post-error accuracy (rather than RT),9,10,42 we expected that the
Laming effect and post-error (but not post-correct) accuracy
scores would show signiﬁcant ﬁndings. Moreover, we expected
the (baseline) Laming effect to predict maladaptive (brooding) but
not adaptive (reﬂection) forms of rumination at discharge.
Results
See Supplementary Material for data on the basic ﬂanker effects,
indicating the task elicited the intended effects.
Treatment effects
Treatment efﬁcacy: Table 1 summarizes clinical measures at
admission and discharge (see Supplementary Material for details).
In brief, CESD-10, BASIS subscales (depression, self-harm and
psychosis), ACS, RRS brooding and CBT skills signiﬁcantly
improved from Time 1 to Time 2. These results support the
efﬁcacy of the treatment.
Post-error adjustments: accuracy: As shown in Figure 1a, post-
error accuracy increased from Time 1 to Time 2, but there was
little change in post-correct accuracy. The Time×Condition
ANOVA returned a signiﬁcant interaction (F(1,31) = 4.75,
P= 0.037). The interaction remained signiﬁcant when a between-
subject factor was included to differentiate patients tested
with (n= 23) versus without (n= 9) block-by-block feedback
(F(1,30) = 14.24, P= 0.001). No other effects were signiﬁcant.
Post hoc t-tests showed that at Time 1, post-error accuracy
(0.92 ± 0.02) was signiﬁcantly lower than post-correct accuracy
(0.96 ± 0.01) (t(31) =− 2.10, P= 0.044). By Time 2, this difference
was not signiﬁcant (t(31) = 1.07, P40.29). Accordingly, the Laming
effect increased from Time 1 (−0.04 ± 0.02) to Time 2 (0.01 ± 0.01)
(t(31) = 2.18, P= 0.037). Post-error accuracy was also higher at Time
2 (0.96 ± 0.01) than Time 1 (0.92 ± 0.02), although this effect was
only marginally signiﬁcant (t(31) = 1.88, P= 0.07).
Post-error adjustments: RT: As shown in Figure 1b, RT was faster
at Time 2 (345.34 ± 6.93) than Time 1 (368.14 ± 7.66ms), and for
post-correct (353.33 ± 6.59 ms) versus post-error (360.16 ± 7.60)
trials. Accordingly, the Time×Condition ANOVA revealed signiﬁ-
cant effects of Time (F(1,31) = 27.09, Po0.001) and Condition (F
(1,31) = 5.73, P= 0.023). The interaction was, however, not
signiﬁcant (Fo1, P= 0.78).
Regression analyses. None of the regression analyses testing the
Rabbitt RT effect as a predictor were signiﬁcant, and none of the
analyses predicting Time 2 CESD-10 scores were signiﬁcant. Thus,
Table 1. Self-report measures in Study 1
Time 1 Time 2 N T-value P-value
Mean s.d. Mean s.d.
RRS
Brooding
Subscore
14.26 2.88 11.52 3.44 23 3.497 0.002
Reﬂection
Subscore
12.87 2.55 12.39 2.50 23 0.794 0.436
Total 63.57 8.61 53.17 11.10 23 3.707 0.001
ACS 43.57 9.58 48.43 10.22 23 − 3.063 0.006
CESD-10 18.65 6.15 9.81 5.69 31 8.398 0.001
BASIS-24
Depression 2.58 0.83 1.59 0.72 31 8.231 0.001
Relationships 1.26 0.71 1.26 0.85 31 -.029 0.977
Self-harm 0.73 0.74 0.45 0.66 30 2.168 0.039
Emotional
lability
1.58 1.05 1.36 0.91 30 1.383 0.177
Psychosis 0.40 0.80 0.20 0.49 29 2.159 0.040
Substance
abuse
0.50 0.86 0.28 0.39 31 1.826 0.078
Total 1.73 0.61 1.13 0.39 28 6.647 0.001
CBT Scale
Behavioral
activation
17.10 5.18 24.90 5.94 30 − 6.612 0.001
Cognitive
restructuring
23.10 6.76 33.80 6.96 30 − 7.631 0.001
Total 40.20 10.58 58.70 12.27 30 −7.563 0.001
Abbreviations: ACS, Attentional Control Scale; BASIS-24, Behavior and
Symptom Identiﬁcation Scale; CBT Scale, Cognitive-Behavioral Therapy
Skills Questionnaire; CESD-10, Center for Epidemiologic Studies Depression
Scale-10; RRS, Ruminative Responses Scale.
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post-error behavioral adjustments measured at baseline did not
predict treatment outcomes as measured by the CESD-10.
Post-error adjustments: accuracy: The Time 1 Laming effect was
a negative predictor of RRS brooding scores (β=− 0.520;
ΔR2 = 0.24, ΔF(1,17) = 5.88, P= 0.027) and a positive predictor of
ACS scores (β= 0.370; ΔR2 = 0.11, ΔF(1,17) = 4.53, P= 0.048) at Time
2. The model considering adaptive forms of rumination (RRS
reﬂection) as the criterion was not signiﬁcant (P40.54). Thus,
larger Laming effects (that is, bigger post-error minus post-correct
accuracy differences) at Time 1 predicted reduced brooding and
increased attentional control at Time 2 after accounting for
brooding and attentional control at Time 1 and depressive
symptoms at both times.
To test the speciﬁcity of these ﬁndings, four additional
hierarchical regressions were run in which the Laming effect
was replaced by post-error or post-correct accuracy. RRS brooding
was signiﬁcantly predicted by post-error accuracy (β= -0.561;
ΔR2 = 0.25, ΔF(1,17) = 6.30, P= 0.022) but not by post-correct
accuracy (β=− 0.167; ΔR2 = 0.021, ΔF(1,17) = 0.41, P40.53). More-
over, the Pearson correlation coefﬁcient between Time 1 post-
error accuracy and Time 2 RRS brooding was signiﬁcant (r=
− 0.470, Po0.035; Figure 1c), but there was no such correlation
with Time 1 post-correct accuracy (r=− 0.08, P40.60).
Furthermore, these two dependent correlations were signiﬁcantly
different (Z= 1.91, 1-tailed, Po0.05). Along similar lines, ACS
scores were signiﬁcantly predicted by post-error accuracy
(β= 0.407; ΔR2 = 0.12, ΔF(1,17) = 5.13, P= 0.037) but not by post-
correct accuracy (β= 0.111; ΔR2 = 0.01, ΔF(1,17) = 0.36, P= 0.55).
This is notable because it suggests that improvements in post-
error adjustment—rather than a global improvement in perfor-
mance—are responsible for the observed relationships with
attentional control and brooding.
STUDY 2: RODENTS
Animals
The novel analysis described here was performed on a data set
used previously to study attention as reﬂected by a variety of
more traditional metrics, as described.15 In brief, a total of 11 male
Sprague–Dawley rats (Charles River Laboratories, Raleigh, NC, USA)
weighing 250–275 g were used for the analysis. Rats were housed
in pairs and kept on a 12-h light–dark cycle with lights on at
0700 hours. All behavioral procedures were conducted during the
light cycle. Rats were food restricted to 85% of their free-feeding
weight throughout the experiment and had free access to water.
The experiments were approved by the McLean Hospital
Institutional Animal Care and Use Committee and conducted in
accordance with National Institutes of Health guidelines.
5CSRTT
Rats were trained to detect the location of a brief stimulus light
(0.5 s) presented randomly in one of ﬁve apertures, and nose-poke
in the correct aperture within 5 s of the stimulus light presenta-
tion. Correct responses were rewarded with a food pellet (45 mg;
BioServ, Frenchtown, NJ, USA) delivered to a food reward
receptacle on the opposite wall. Incorrect responses and
omissions resulted in a 5-s timeout. Tests consisted of 90 trials
or 30 min, whichever came ﬁrst. The criteria for stable responding
was 460% correct responses and o20% omissions for ﬁve
consecutive days.
Surgical procedures
Once rats reached criteria, they underwent surgery to implant an
intracerebroventricular cannula for drug delivery. Rats were
anesthetized with pentobarbital (65 mg kg− 1) and placed in a
stereotaxic instrument. A stainless steel guide cannula (23 gauge,
Plastics One, Roanoke, VA, USA) with a dummy stylet extending
1.5 mm beyond the cannula tip was lowered into the right lateral
ventricle (relative to bregma: − 0.8 mm anteroposterior, 1.3 mm
mediolateral and − 3.5 mm ventral to dura) and attached to
the skull.
Drugs and experimental design
After 5–7 days of recovery and restabilization of performance, rats
ﬁrst received a microinfusion of vehicle (artiﬁcial CSF; Harvard
Apparatus, Holliston, MA, USA) to obtain baseline metrics.
Following restabilization between infusions, rats (n= 6) were then
infused with CRF over a range of doses to identify those that
produce minimal, intermediate and asymptotic responses (0.25–
1.0 μg; American Peptide, Sunnyvale, CA, USA). All infusions were
delivered over a 2-min period at a rate of 0.5 μl min− 1. Rats were
tested in the 5CSRTT 60min after infusion. In a separate cohort,
rats (n= 5) received an intraperitoneal injection of JDTic (10 -
mg kg− 1; Research Triangle Park, NC, USA) dissolved in 0.9% saline
48 h before CRF or vehicle (VEH) infusions to determine whether
systemic administration of the KOR antagonist JDTic blocks the
disruptive (depressive-like) effects of CRF.
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Figure 1. Post-correct and post-error (a) accuracy and (b) reaction
time scores (in ms) at Time 1 (ﬁrst day of admission to treatment
program) and Time 2 (post treatment) for patients. *Po0.05,
***Po0.001, post hoc t-tests. (c) Correlation between Time 1 post-
error accuracy and Time 2 RRS (Ruminative Responses Scale)
brooding.
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Data analysis
Error analysis was limited to data collected after treatment with
vehicle or 0.5 μg CRF, because this dose was shown to induce
intermediate performance deﬁcits in traditional 5CSRTT metrics
that were attenuated by JDTic pretreatment.15 Other doses tested
previously produced negligible or asymptotic effects. To deter-
mine whether CRF treatment in rats causes deﬁcits in post-error
adjustments as described in depressed samples (see also Holmes
and Pizzagalli10), post-error accuracy ( =% correct/total trials
following an incorrect response) and post-correct accuracy ( =%
correct/total trials following a correct response) were calculated. A
Treatment (VEH and CRF) × Condition (post-error and post-correct)
ANOVA was run separately for accuracy and RT with repeated
measures on Treatment. Effects of CRF on post-error accuracy was
analyzed with preplanned contrasts (Bonferroni tests) between
VEH and CRF treatment days based on a speciﬁc a priori
hypothesis that CRF treatment would produce similar
depressive-like post-error adjustments as seen in humans. A
similar analysis was run for the studies involving JDTic
pretreatment.
Results
Consistent with our a priori hypothesis that the stress-peptide CRF
would impair post-error adjustments in a manner similar to what
observed in depressed human subjects, preplanned (Bonferroni)
contrasts between CRF- and VEH-treated rats revealed that CRF
treatment decreased post-error accuracy (34.34 ± 9.11) compared
with VEH treatment (66.51 ± 5.64; Po0.01) without producing a
signiﬁcant change in post-correct accuracy (55.79 ± 6.71 and
73.91 ± 3.91, respectively; Figure 2a). The ANOVA revealed a main
effect of Treatment (F(1,10) = 18.24, Po0.002) and a marginal
effect of Condition (F(1,10) = 3.94, P= 0.075). Unlike the human
data, however, the Treatment × Condition interaction was not
signiﬁcant (F(1,10) = 1.42, P= 0.26). Moreover, CRF treatment
increased latency regardless of Condition: while the Treatment ×
Condition interaction for RT was not signiﬁcant (F(1,10) = 3.79,
P= 0.08), there was a main effect of Treatment (F(1,10) = 16.29,
P= 0.0024).
There were no signiﬁcant differences between rats treated with
JDTic and VEH, and rats treated with JDTic and CRF in post-correct
or post-error accuracy (Figure 2c). The main effect of Treatment
was not signiﬁcant (F(1,10) = 3.35, P= 0.105), and neither was the
interaction (F(1,10) = 0.18, P= 0.68). There were also no signiﬁcant
differences on post-correct or post-error latency (Figure 2d). The
main effect of Treatment was not signiﬁcant (F(1,10) = 0.08,
P= 0.78) nor was the interaction (F(1,10) = 0.0008, P= 0.98). These
results are consistent with accumulating evidence that KOR
antagonism has antidepressant-like effects in rodent models used
to study depression.43
DISCUSSION
Depression has been linked to impairments in cognitive control,
particularly deﬁcits in adjusting behavior after errors or negative
feedback.7–11 However, the clinical concomitants and neurobiolo-
gical substrates of this impairment are largely unknown. We used
a translational, cross-species approach to examine the robustness
of this impairment in a real-world depressed sample and in
rodents, as well as whether treatment can improve post-error
processing in both species. First, in the depressed sample,
accuracy for post-error trials was signiﬁcantly lower than for
post-correct trials at Time 1, thus replicating prior ﬁndings in
subclinical9,42 and clinical samples recruited from the community
(for example, Holmes and Pizzagalli,10 and Steffens et al.11).
Second, we report the novel ﬁnding that CRF administration in
rats, previously found to elicit a depression-like phenotype,
signiﬁcantly reduces accuracy after incorrect but not correct
responses, providing evidence that error-processing deﬁcits
observed in depressed humans can be mimicked in a rodent
model that elicits depression-like phenotypes. Third, as expected,
provision of treatment in humans (CBT and pharmacological) and
rodents (pharmacological) was effective in improving post-error
accuracy.
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Figure 2. Post-correct and post-error (a) accuracy (reﬂected by % correct) and (b) latency (in ms) for vehicle (VEH)-treated and corticotropin-
releasing factor (CRF)-treated rats, and (c) accuracy and (d) latency for VEH and CRF-treated rats with JDTic pretreatment. *Po0.05, post hoc
Bonferroni tests; **Po0.01, main effect of Treatment.
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To the best of our knowledge, this is the ﬁrst report that
treatment may impact post-error behavioral adjustment. Although
the 4% increase in post-error accuracy in patients from pre- to
post treatment was small in magnitude (d= 0.457), it is compar-
able to the between-group difference observed in prior studies
comparing post-error accuracy in patients with major depressive
disorder and healthy controls.10 Additional analyses in the patient
sample further suggested that impaired post-error adjustments
predicted functional outcome after treatment. Although post-error
accuracy at baseline did not predict depressive symptoms
following treatment, it did predict both reduced brooding and
increased attentional control at post treatment. These ﬁndings are
noteworthy because the demand for cognitive control is higher on
post-error versus post-correct trials. Selective relationships
between post-error accuracy at baseline and treatment effects
on RRS brooding and ACS scores suggest an important role for
baseline cognitive control in treatment outcomes.
Post-error accuracy was decreased in rats given a manipulation
known to produce hallmark signs of depression and anxiety,
resembling the pattern seen in the patient study. Speciﬁcally, CRF
(which produces signs of depression in humans and depressive-
like signs in rodents15) degraded post-error accuracy. Notably, the
disruptive effect of CRF on post-error accuracy was not evident in
rats pretreated with JDTic, a KOR antagonist with antidepressant-
and anxiolytic-like effects in rodents.24 Although the general
patterns of responding seen after CRF alone and those seen after
JDTic plus CRF have similarities, KOR antagonist treatment
reduced the magnitude of impairment in post-error accuracy
(49% reduction versus 33% reduction). Thus, consistent with the
human data, intervention can mitigate impairments in cognitive
control. To the extent that the basic behavioral patterns seen in
rats treated with CRF resemble those seen in depressed
humans,18–21 our data suggest that KOR antagonism may relieve
certain cognitive deﬁcits that accompany mood disorders.
The current ﬁndings should be considered in the context of the
study design. First, the patient data stemmed from a naturalistic
treatment setting. This provides an important test of post-error
behavioral adjustment in depression, as the sample was
characterized by severe psychopathology, high comorbidity,
medication use and suicidal ideation. Moreover, in line with the
Research Domain Criteria approach, we did not limit our sample to
a particular mood disorder diagnosis. Although these decisions
maximize the external validity of the study and allow a test of
post-error processing in a real-world sample, they introduce
several important caveats. First, the treatment received by the
patients was uncontrolled and included various types of medica-
tion and CBT groups. Moreover, given the sample size, we did not
have adequate power to control for the various combinations of
treatments. Still, the fact that hypothesized ﬁndings emerged in
such heterogeneous sample is noteworthy. Second, because we
utilized a naturalistic treatment sample without a control group,
we cannot rule out the possibility that pre-post changes in
symptoms were due to regression to the mean or demand effects.
Given this study design, we also cannot determine which aspects
of treatment were involved in any post-error processing improve-
ment. In addition, it is possible that improvements in post-error
performance were due simply to practice effects. However, the
speciﬁcity of the accuracy ﬁndings with respect to trial type (post-
error versus post-correct trials) and constructs (for example,
maladaptive versus adaptive forms of rumination) makes demand
or practice effects less likely. Nonetheless, future studies with a
control psychiatric sample not receiving treatment are warranted.
Third, the current real-world patient sample resulted in a greater
percentage of patients not meeting data quality cutoffs (e.g.,
making enough, but not too many errors to examine these effects)
compared with previous studies of unmedicated and comorbidity-
free community samples. Thus, while our ‘real-world’ sample
enhances generalizability to comorbid, chronic and medicated
patients, the higher exclusion rate may also limit generalizability.
Importantly, patients excluded for quality cutoffs did not differ
from included patients on baseline levels of depression, anxiety,
functioning, CBT skills or demographic variables. Fourth, although
depression was the focus of treatment, a number of the patients
had comorbid anxiety disorders. Impairments in cognitive control,
and speciﬁcally abnormal error processing, have also been
implicated in anxiety disorders (for example, Weinberg et al. 44).
Thus, it is possible that anxiety symptoms also contributed to the
abnormal error processing observed in the current study.
Finally, the patient study and rodent study were not designed
as complementary experiments. Although we acknowledge that
these rodent studies were not speciﬁcally intended to examine
post-error performance, reanalysis of our existing data demon-
strates an important proof of concept without requiring the use of
additional experimental animals, and highlights the translational
power of post-error processing in models of depressive pheno-
types across species. Because these data were from a previously
published report in which we studied the mechanisms by which
stress degrades attention,15 we had two separate cohorts of rats
available for the reanalysis, which enabled us to examine the
effects of a KOR antagonist on post-error performance. It is
conceivable that more thorough dose–effect functions for both
CRF and JDTic in tests speciﬁcally designed to examine post-error
accuracy could reveal more prominent effects.
These limitations notwithstanding the current ﬁndings are
novel and suggest several areas of future research. For example, as
studies have shown that computer-based cognitive training may
be able to improve cognitive functioning in patients with major
depressive disorder,45,46 such training may be especially beneﬁcial
for individuals with poor post-error behavioral adjustments. More
generally, identiﬁcation of cognitive domains in depressed
humans that have analogs in rodents in depressive-like states
has become a high priority for modeling mood disorders in
laboratory animals.47 The neural substrates of these effects can be
examined in great detail in rodents, with the goal of identifying
brain structures or mechanisms that could be targeted by new
types of therapeutic intervention. In this context, and in light of
prior electrophysiological data linking impaired post-error proces-
sing with dysfunction within frontocingulate pathways,10 it will be
important to test in future studies whether KOR antagonists might
exert antidepressant effects by normalizing brain circuitry critically
implicated in cognitive control.
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